阿司匹林用于一级预防与心血管事件及出血事件的关联:系统评价与Meta分析
该系统评价与Meta分析检索截至2018年11月1日的PubMed、Embase和Cochrane图书馆,纳入13项随机临床试验、共164225例无已知心血管疾病的参与者,随访1050511人年。阿司匹林组复合心血管结局(心血管死亡、非致死性心肌梗死、非致死性卒中)发生率为57.1/10000人年,对照组为61.4/10000人年(HR 0.89,95%可信区间0.84-0.95;绝对风险降低0.38%,NNT 265)。阿司匹林组大出血发生率为23.1/10000人年,对照组为16.4/10000人年(HR 1.43,95%可信区间1.30-1.56;绝对风险增加0.47%,NNH 210)。作者认为该信息可用于与患者讨论阿司匹林用于心血管事件一级预防的获益与出血风险。
要点
- 无心血管疾病人群使用阿司匹林与复合心血管结局风险降低相关:阿司匹林组57.1/10000人年 vs 无阿司匹林组61.4/10000人年,HR 0.89(95%可信区间0.84-0.95),NNT 265。
- 同一人群使用阿司匹林与大出血风险升高相关:阿司匹林组23.1/10000人年 vs 无阿司匹林组16.4/10000人年,HR 1.43(95%可信区间1.30-1.56),NNH 210。
- 绝对风险降低0.38%(95%CI 0.20%-0.55%),绝对风险增加0.47%(95%CI 0.34%-0.62%),出血绝对风险增加幅度大于心血管绝对风险降低幅度。
- 纳入试验中位年龄62岁(范围53-74岁),47%为男性,19%有糖尿病,中位基线主要心血管结局风险9.2%(范围2.6%-15.9%)。
- 作者认为该信息可用于与患者讨论阿司匹林用于心血管事件一级预防的获益与出血风险。
适用人群与场景
- 纳入标准:随机临床试验入组至少1000例无已知心血管疾病的参与者,随访至少12个月。
- 纳入试验中位年龄62岁(范围53-74岁),77501例(47%)为男性,30361例(19%)有糖尿病,中位基线主要心血管结局风险9.2%(范围2.6%-15.9%)。
- 研究场景为一级预防,即无已知心血管疾病人群。
研究设计与关键结果
- 研究类型:系统评价与Meta分析,纳入13项随机临床试验,共164225例参与者,随访1050511人年。
- 干预与对照:阿司匹林 vs 无阿司匹林(安慰剂或无治疗)。
- 主要心血管终点(心血管死亡、非致死性心肌梗死、非致死性卒中的复合终点):阿司匹林组57.1/10000人年 vs 无阿司匹林组61.4/10000人年,HR 0.89(95%可信区间0.84-0.95),绝对风险降低0.38%(95%CI 0.20%-0.55%),NNT 265。
- 主要出血终点(各研究定义的大出血):阿司匹林组23.1/10000人年 vs 无阿司匹林组16.4/10000人年,HR 1.43(95%可信区间1.30-1.56),绝对风险增加0.47%(95%CI 0.34%-0.62%),NNH 210。
- 采用贝叶斯和频率学派Meta分析方法。
证据类型、等级与局限
- 证据类型:系统评价与Meta分析,纳入13项随机临床试验。
- 检索数据源:PubMed、Embase和Cochrane图书馆对照试验中心注册库,检索截至2018年11月1日。
- 局限:原文未报告局限性。
对床旁实践的改变
- 作者认为,该信息可用于与患者讨论阿司匹林用于心血管事件一级预防的获益与出血风险。
- 原文未据此给出推荐。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
IMPORTANCE: The role for aspirin in cardiovascular primary prevention remains controversial, with potential benefits limited by an increased bleeding risk.
OBJECTIVE: To assess the association of aspirin use for primary prevention with cardiovascular events and bleeding.
DATA SOURCES: PubMed and Embase were searched on Cochrane Library Central Register of Controlled Trials from the earliest available date through November 1, 2018.
STUDY SELECTION: Randomized clinical trials enrolling at least 1000 participants with no known cardiovascular disease and a follow-up of at least 12 months were included. Included studies compared aspirin use with no aspirin (placebo or no treatment).
DATA EXTRACTION AND SYNTHESIS: Data were screened and extracted independently by both investigators. Bayesian and frequentist meta-analyses were performed.
MAIN OUTCOMES AND MEASURES: The primary cardiovascular outcome was a composite of cardiovascular mortality, nonfatal myocardial infarction, and nonfatal stroke. The primary bleeding outcome was any major bleeding (defined by the individual studies).
RESULTS: A total of 13 trials randomizing 164 225 participants with 1 050 511 participant-years of follow-up were included. The median age of trial participants was 62 years (range, 53-74), 77 501 (47%) were men, 30 361 (19%) had diabetes, and the median baseline risk of the primary cardiovascular outcome was 9.2% (range, 2.6%-15.9%). Aspirin use was associated with significant reductions in the composite cardiovascular outcome compared with no aspirin (57.1 per 10 000 participant-years with aspirin and 61.4 per 10 000 participant-years with no aspirin) (hazard ratio [HR], 0.89 [95% credible interval, 0.84-0.95]; absolute risk reduction, 0.38% [95% CI, 0.20%-0.55%]; number needed to treat, 265). Aspirin use was associated with an increased risk of major bleeding events compared with no aspirin (23.1 per 10 000 participant-years with aspirin and 16.4 per 10 000 participant-years with no aspirin) (HR, 1.43 [95% credible interval, 1.30-1.56]; absolute risk increase, 0.47% [95% CI, 0.34%-0.62%]; number needed to harm, 210).
CONCLUSIONS AND RELEVANCE: The use of aspirin in individuals without cardiovascular disease was associated with a lower risk of cardiovascular events and an increased risk of major bleeding. This information may inform discussions with patients about aspirin for primary prevention of cardiovascular events and bleeding.
参考来源
- Zheng SL, Roddick AJ. Association of Aspirin Use for Primary Prevention With Cardiovascular Events and Bleeding Events: A Systematic Review and Meta-analysis. JAMA. 2019. PMID: 30667501. doi:10.1001/jama.2018.20578
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。